Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.3 CHF | +0.12% | -1.10% | +14.16% |
Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
Apr. 04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
Business Summary
Number of employees: 147
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Pharmaceutical Products
100.0
%
| 148 | 100.0 % | 158 | 100.0 % | +6.68% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Ireland
43.6
%
| 41 | 27.9 % | 69 | 43.6 % | +66.34% |
Japan
37.8
%
| 64 | 43.3 % | 60 | 37.8 % | -6.87% |
Uruguay
6.5
%
| 7 | 5.0 % | 10 | 6.5 % | +37.84% |
United States
3.9
%
| 10 | 6.6 % | 6 | 3.9 % | -37.76% |
Sweden
2.5
%
| 3 | 2.2 % | 4 | 2.5 % | +21.87% |
Canada
2.3
%
| 3 | 1.9 % | 4 | 2.3 % | +28.57% |
China
1.5
%
| - | - | 2 | 1.5 % | - |
Jordan
1.1
%
| 3 | 1.8 % | 2 | 1.1 % | -33.33% |
Switzerland
0.9
%
| 2 | 1.6 % | 1 | 0.9 % | -41.67% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Marc Engelhardt
CTO | Chief Tech/Sci/R&D Officer | 60 | 09-12-31 |
Chief Tech/Sci/R&D Officer | 57 | 99-12-31 | |
Investor Relations Contact | - | - | |
Damian Heller
LAW | General Counsel | 58 | 14-12-31 |
Ursula Eberhardt
HRO | Human Resources Officer | 62 | 05-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 | |
Domenico Scala
CHM | Chairman | 58 | 11-11-28 |
Carole A. Sable
BRD | Director/Board Member | 62 | 23-04-26 |
Thomas Werner
BRD | Director/Board Member | 68 | 11-11-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,079,793 | 11,974,303 ( 91.55 %) | 1,098,157 ( 8.396 %) | 91.55 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
BASILEA PHARMACEUTICA AG 8.33% | 1,091,643 | 8.33% | 45,631,573 $ |
Company contact information
Basilea Pharmaceutica AG
Hegenheimermattweg 167b
4123, Allschwil
+41 61 606 11 11
http://www.basilea.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.16% | 529M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BSLN Stock
- Company Basilea Pharmaceutica AG